RESEARCH ALERT - UroQuest , ADAC rated buys . - - Dillon , Read & Co said analysts Raul Esquivel and Matthew Dodds initiated coverage of UroQuest Medical Inc and ADAC Laboratories with buy ratings . - - The analysts put a one - year price target of $ 18 - $ 20 per share on UroQuest , which makes products used to diagnose and manage urological disorders . - - Dillon , Read was lead underwriter for Uroquest ' s October initial public offering at $ 6 a share . Shares were trading flat Wednesday at six . - - The analysts put a one - year price target of $ 24 - $ 26 on ADAC , a nuclear medicine company . It was up 1 / 2 at 19 - 7 / 8 . 
